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Summary
The 9.5 MDa human pyruvate dehydrogenase complex
(PDC) utilizes the specific dihydrolipoamide dehydro-
genase (E3) binding protein (E3BP) to tether the es-
sential E3 component to the 60-meric core of the com-
plex. Here, we report crystal structures of the binding
domain (E3BD) of human E3BP alone and in complex
with human E3 at 1.6 A˚ and 2.2 A˚, respectively. The lat-
ter structure shows that residues from E3BD contact
E3 across its 2-fold axis, resulting in one E3BDbinding
site on the E3 homodimer. Negligible conformational
changes occur in E3BD upon its high-affinity binding
to E3. Modifications of E3BD residues at the center
of the E3BD/E3 interface impede E3 binding far more
severely than those of residues on the periphery, vali-
dating the ‘‘hot spot’’ paradigm for protein inter-
actions. A cluster of disease-causing E3 mutations
located near the center of the E3BD/E3 interface pre-
vents the efficient recruitment of these E3 variants
by E3BP into the PDC, leading to the dysfunction of
the PDC catalytic machine.
Introduction
The mammalian mitochondrial pyruvate dehydrogenase
complex (PDC) catalyzes the oxidative decarboxylation
of pyruvate to give rise to acetyl-CoA, NADH and CO2
(Reaction 1).
CH3eCOeCOOH + CoAeSH + NAD
+
/CH3eCOeSeCoA + CO2 + NADH + H
+ (1)
FAD and lipoyl moieties are used as a coenzyme and
a prosthetic group, respectively, by PDC. The overall re-
action links glycolysis to the energy-producing Krebs
cycle and lipogenic pathways. PDC is a member of the
highly conserved mitochondrial a-ketoacid dehydro-
genase complexes, which comprise the PDC, the
branched-chain a-ketoacid dehydrogenase complex
(BCKDC), and the a-ketoglutarate dehydrogenase com-
plex (KGDC) (Patel and Roche, 1990; Reed, 2001; Reed
et al., 1985). The mammalian PDC is a 9.5 3 106 Da nu-
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david.chuang@utsouthwestern.edu (D.T.C.)clear-encoded macromolecular machine organized
around an icosahedral 60-meric transacetylase (E2p)
core. To the E2p core, 30 copies of heterotetrameric py-
ruvate dehydrogenase (E1p), 12 copies of homodimeric
dihydrolipoamide dehydrogenase (E3), and 12 copies of
monomeric E3 binding protein (E3BP) are attached via
noncovalent protein-protein interactions (Reed, 2001).
Each E2p subunit consists of two lipoyl-bearing do-
mains (LBDs), one subunit binding domain (SBDp) that
binds E1p, and one inner-core domain that contains
the E2p active site and is responsible for the self-assem-
bly of the core. Of the above PDC components, E1p,
E2p, and E3BP are specific for PDC, whereas E3 is com-
mon to all a-ketoacid dehydrogenase complexes. The
overall reaction of PDC (Reaction 1) is achieved by the
substrate-channeled summation of the individual reac-
tions of the three catalytic components. In addition, un-
specified copies of pyruvate dehydrogenase kinase and
pyruvate dehydrogenase phosphatase, which are asso-
ciated primarily with the second lipoyl-bearing domain
of the E2p core, regulate PDC activity by reversible
phosphorylation (Reed et al., 1985; Roche et al., 2003).
Because of its central importance in intermediary me-
tabolism, mutations in the genes coding for subunits of
human PDC produce severe clinical phenotypes (Robin-
son, 2001). Congenital defects in the gene for human
E1p result in neonatal lactic acidemias and encephalop-
athies (Robinson, 2001). Mutations in the gene encoding
human E3BP have also been reported (Aral et al., 1997;
Dey et al., 2002, 2003; Ling et al., 1998). These mutations
invariably result in the absence of the E3BP protein. The
null phenotype for E3BP leads to congenital PDC defi-
ciency as characterized by the above clinical manifesta-
tions (Robinson, 2001). Errors in the gene coding human
E3 cause combined deficiencies in a-ketoacid dehydro-
genase complexes manifested by lactic acidemias and
Maple Syrup Urine Disease (Chuang and Shih, 2001;
Hengeveld and de Kok, 2002; Odievre et al., 2005). A
subset of the human E3 mutations has been suggested
to occur at the homodimer interface (Hong et al., 1996,
1997; Shany et al., 1999) or at the putative E3/E3BP
(Odievre et al., 2005) interaction surface. The clinical
consequences resulting from these mutations are simi-
lar to those caused by the E3BP null mutations. Addi-
tionally, the aberrant downregulation of PDC activity
by reversible phosphorylation contributes to hypergly-
cemic states observed in type-2 diabetes (Holness and
Sugden, 2003), raising the prospect that the PDC repre-
sents a therapeutic target for a disease that afflicts over
150 million people worldwide (Wild et al., 2004).
The fundamental metabolic and clinical importance
of PDC has prompted the examination of its macromo-
lecular structure. Three-dimensional reconstructions of
yeast PDC derived from cryoelectron microscopy
show that 12 copies of E3BP are buried inside the 12
pentagonal openings of the truncated E2p scaffold,
with each of the 12 E3 homodimers bound to a single
E3BP monomer (Reed, 2001; Stoops et al., 1997). In
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core domain of bovine E3BP, which has a significantly
longer C-terminal extension than its yeast counterpart,
is integrated into the 60-meric core of the bovine PDC
with an E2p: E3BP = 48: 12 subunit stoichiometry (Hiro-
masa et al., 2004). The structural basis for the funda-
mental differences in the organization of E3BP between
yeast and mammalian PDC is unknown.
Only a few high-resolution studies of the structural de-
tails of the vital intersubunit interactions of PDC are
available. The structure of the SBDp of E2p from the
Geobacillus stearothermophilus (formerly Bacillus
stearothermophilus) PDC bound to its cognate E3
shows that a single SBDp binds near to the 2-fold axis
of the E3 homodimer (Mande et al., 1995). This mode
of binding sterically excludes the binding of a second
SBDp. In this Geobacillus SBDp/E3 complex, the inter-
action between the two proteins consists largely of elec-
trostatic interactions between one a-helix of the SBDp
and surface residues of E3. SBDp is also responsible
for securing the E1p to the Geobacillus PDC, and E1p
as well as E3 bind to SBDp in a mutually exclusive
mode (Reed, 2001; Perham, 2000). A recent SBDp/E1p
complex structure of Geobacillus PDC demonstrates
that the electrostatic nature of the SBDp/E3 interface
is conserved, but much less surface area is buried at
the SBP/E1p interface than that of the SBDp/E3 (Frank
et al., 2005).
Unlike Geobacillus stearothermophilus and other pro-
karyotes, eukaryotes require a separate protein, E3BP,
to tether E3 to the PDC. E3BP was previously desig-
nated ‘‘protein X’’ because its biological function was
unknown when it was first discovered (De Marcucci
and Lindsay, 1985; Jilka et al., 1986). The identity and
the E3-tethering function of E3BP was established by
limited proteolysis (Gopalakrishnan et al., 1989;
Powers-Greenwood et al., 1989) and later confirmed
by disruption and mutagenesis of the gene encoding
yeast E3BP (Lawson et al., 1991). The domain structure
of human E3BP is similar to that of human E2p (Aral
et al., 1997; Harris et al., 1997; Ling et al., 1998); at the
N terminus is a single LBD, followed by the E3 binding
domain (E3BD) and the C-terminal domain. The C-termi-
nal domain of E3BP shows about 50% sequence identity
to its counterpart in human E2p. The covalently attached
lipoyl moiety in E3BP (Neagle et al., 1989; Powers-
Greenwood et al., 1989), like those of E2p, is competent
to serve as a coenzyme in the PDC reaction (Hodgson
et al., 1986; Jilka et al., 1986; Rahmatullah and Roche,
1987). The inner-core domain of E2p harbors a histidine
residue that is essential for its transacetylase activity.
This residue is not conserved in E3BP, and this protein
therefore does not possess transacetylase activity.
In this study, we present crystal structures of human
E3BD alone and in complex with E3 of the human PDC
at resolutions of 1.6 A˚ and 2.2 A˚, respectively. These
structures show that E3BD is structurally similar to
SBDs and that it rigidly associates with E3 using a com-
plex network of interactions. Alanine-scanning muta-
genesis of E3BD residues involved in the E3BD/E3 inter-
actions and subsequent binding studies further validate
the nature of the association between E3BD and E3.
Moreover, we show that a subset of disease-causing hu-
man E3 mutations, which are located at the E3BD/E3interface, disrupt the binding of E3 to the E2p core, re-
sulting in dysfunction of the PDC.
Results and Discussion
The Crystal Structure of E3BD: Similarity
to the SBD Fold
The human E3BP comprises one copy each of an LBD
(residues 1–84), E3BD (residues 130–170), and the in-
ner-core (residues 222–448) domains (Figure 1A). These
domains are connected by flexible linker regions. The
1.55 A˚ crystal structure of the E3BP region (residues
121–175) harboring the E3BD has been determined.
This was accomplished via molecular replacement us-
ing the structure of 43 amino acids of human E3BD
known from the bound structure (see below) as the
search model (Table 1; Figure 1B). In the model, residues
121–126 are ordered but do not form regular secondary
structure. Residues 127–130 form a small a-helix (H0),
which is followed by a loop (L0) comprising residues
131–132 of E3BD. The a-helix H1 of the binding domain
ranges from residues 133 to 141. After H1, there is a short
region devoid of regular secondary structure (residues
142–145, termed L1). A small 310 helix (residues 146–
148) is followed by a second loop (L2; residues 149–
159) with an abrupt turn. The remainder of E3BD is
an a-helix (H2; residues 160–175). Additional vector-
derived amino acids, labeled residues 176–180 in the
construct (see Experimental Procedures), are visible at
the C terminus of H2. H1 and H2 helices are parallel to
each other and form extensive packing interactions.
The structure of E3BD is similar to those of SBDs from
E2s of other a-ketoacid dehydrogenase complexes. The
solution structures of the E2k SBDs from E. coli KGDC
(SBDk) and the Geopbacillus SBDp are known (Allen
et al., 2005; Robien et al., 1992). In addition, the crystal
structures of Geobacillus SBDp in complex with either
the cognate E1p or E3 have been determined (Frank
et al., 2004; Mande et al., 1995). Pairwise comparisons
of the structures reveal that the three domains are struc-
tural homologs (Figure 1C); the largest r.m.s. deviation
between the approximately 40 comparable Ca atoms in
any of the structures when compared to that of E3BD
is 1.6 A˚. An alignment of the three sequences is shown
in Figure 1D.
The Crystal Structure of the E3BD/E3 Complex: Rigid
Structural Association
The binding of E3BD to E3 was characterized by isother-
mal titration calorimetry (ITC). The LBD-E3BD construct
(the LBD of human BCKDC fused to E3BD from human
E3BP; see Experimental Procedures for details) was
used in the present binding experiments. LBD-E3BD
binds tightly to E3, exhibiting a dissociation constant
(Kd) of 7.8 3 10
210 M as measured in the competitive
binding experiment (Figure 2). For high-affinity binding
with Kd < 10
28 M, the presence of a weaker binding
competitor ligand such as the SBDb of human BCKDC
in this ITC measurement is necessary to obtain an accu-
rate dissociation constant from the binding isotherm
(Sigurskjold, 2000). The LBD moiety of human BCKDC in
the fusion construct does not interact with E3, since sim-
ilar Kd values were obtained when either isolated E3BD
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613Figure 1. Crystal Structure of E3BD and Comparison to SBD Struc-
tures
(A) The domain structure of human E3BD. The single lipoyl domain
(LBD, gray), the E3 binding domain (E3BD, green), and the inner
core domain (orange) are connected by flexible linkers (solid lines).
The boxes depict individual domains with numbers of the first and
last residues for each domain indicated.
(B) Ribbon drawing of the crystal structure of E3BD, with helices in
green and areas without regular secondary structure in purple. Parts
of the structure mentioned in the text are labeled.
(C) A stereo diagram of the comparison of the structures of SBDs to
E3BD. Each tube represents a trace through the Cas of the respec-
tive structure. Shown are human E3BD (green), human E3BD from
the E3BD/E3 structure (yellow), the NMR structure of the SBDp
from the E2p of Geobacillus PDC (orange; 1W3D; Allen et al.,
2005), and the NMR structure of the SBDk from the E2k of E. coli
KGDC (blue; 1BBL; Robien et al., 1992).
(D) Sequence alignment of the three structures. The names of the se-
quences retain the color of the structure shown in part (C). The num-
bering is that of human E3BD. Abbreviations: hE3BD, human E3BD;
GsSBDp, Geobacillus SBD from the PDC; EcSBDk, E. coli SBDk
from the E2k of KGDC; hE3, human E3; GsE3, Geobacillus E3;
GsE1p; E1 of the Geobacillus PDC. The residues boxed in purple
are identical in all three structures; regions of similarity identified
by CLUSTALW are boxed in yellow. Above the alignment is a cartoon
representation of the secondary structure of E3BD. Below are
marked the positions of side chains of the binding proteins that con-
tact hE3 (arrowheads), GsE3 (circumflexes), or GsE1p (stars). The
color of the symbols matches the color of the name of the protein
to which the E3 or E1p binds.or LBD-E3BD was titrated against E3 (data not shown).
The binding model with the best fit to the observed bind-
ing isotherm demonstrates one binding site for E3BD
per E3 homodimer. In contrast, the binding of the
SBDp from human E2p to E3 in the absence of the com-
petitor ligand is not measurable due to negligible en-
thalpy changes (Figure 2). These results establish the
specialized role of E3BD in binding human E3.
The 2.2 A˚ crystal structure of E3BD in complex with
human E3 (the E3BD/E3 complex) reveals the interac-
tions between the binding domain and its larger homodi-
meric partner (Figure 3). The structure was determined
using the human E3 homodimer (1ZWD; Brautigam
et al., 2005) as a molecular-replacement search model
(Table 1). Five homodimers were located in the asym-
metric unit of the E3BD/E3 crystals. Following rigid-
body refinement, electron-density maps revealed
density for E3BD bound to all five homodimers of E3.
In most cases, this density was difficult to interpret. In
Table 1. Data Collection and Refinement Statistics
Structure E3BD E3BD/E3
Space Group P6522 P212121
a, A˚ 36.8 171.1
b, A˚ 36.8 187.7
c, A˚ 191.5 224.4
a, b, g, º 90, 90, 120 90, 90, 90
Resolution, A˚a 28.5-1.55
(1.61-1.55)
37.4-2.18
(2.26-2.18)
No. reflections 165,906 1,412,815
Unique reflections (FR0) 12,109 (1117) 367,237 (31492)
Completeness, % 98.9 (95.4) 98.2 (84.8)
Avg. Redundancy 13.7 (7.9) 3.9 (2.5)
Avg. I/s 67.8 (8.6) 21.9 (1.9)
Rsym
b 0.032 (0.148) 0.054 (0.401)
Refinement Statistics
Resolution range, A˚ 28.5-1.55 37.4-2.18
No. reflections used 12,034 367,068
No. protein atoms 561 39,790
No. waters 59 1,415
Rwork
c 0.203 0.211
Rfree
d 0.220 (584) 0.247 (4518)
Average B-factors (A˚2)
Protein 23.5 40.3
E3 N/Af 41.4
E3BD 23.5 49.1
Ligand/ion 52.9 41.1
Water 39.8 38.7
Rms deviations
Bond lengths, A˚ 0.034 0.011
Bond angles, º 2.8 1.5
Ramachandran distributione
Favored, % 100 96.1
Allowed, % 100 98.6
a Numbers in parentheses are for the highest-resolution shell of the
data.
b Rsym =ShSi jI^(h) – Ii(h)j/ShSi Ii(h), where Ii(h) is the ith measurement of
the intensity for Miller indices h and I^(h) represents the mean inten-
sity value of the symmetry- (or Friedel-) equivalent reflections of
Miller indices h.
c Rwork = ShkFobsj 2 jFcalck/ShjFobsj
d The formula for Rfree is the same as that for Rwork, except it is cal-
culated with a portion of the structure factors that had not been
used for refinement. The number of reflections used for calculating
Rfree is indicated in parentheses.
e Using a modified Ramachandran plot (Lovell et al., 2002).
f Not applicable.
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614four out of the five dimers, E3BD apparently binds in two
orientations with respect to the homodimer, and each
orientation is observed in about 50% of the asymmetric
units in the crystal. However, on one homodimer, the
‘‘AB dimer,’’ unambiguous electron density is present
for only one orientation of E3BD, which allowed the trac-
ing of 43 amino acids of E3BD. Using this information,
two E3BDs were positioned on each of the other four ho-
modimers at overlapping binding sites and refined as al-
ternate conformations of one another, with occupancies
of approximately 0.5 (the occupancies were refined). It is
important to note that the two conformations therefore
represent a single E3BD binding to these E3 homo-
dimers in two possible orientations. The occupancy of
the lone E3BD bound to the AB dimer is 1.0. Although
we limit our discussion below to the AB-dimer/E3BD in-
terface, the observations hold for all copies of E3 and
E3BD in the asymmetric unit. As modeled above, the
Figure 2. Binding of E3BD and SBDp to Human E3 Measured by Iso-
thermal Titration Calorimetry
The upper panel shows raw data of heat changes for the titration of
LBD-E3BD (blue tracing) or LBD-SBDp (red tracing) into E3 in the cell
in the presence and absence of a competitor ligand LBD-SBDb (from
human BCKDC), respectively. The lower panel represents the bind-
ing isotherms for each injection versus the molar ratio of the LBD-
E3BD monomer (blue circles) or the LBD-SBDp monomer (red circles)
to the E3 dimer. The solid line in the lower panel depicts the fitting of
the binding isotherms for LBD-E3BD and LBD-SBDp, based on a sin-
gle-site binding model using the ORIGIN v. 7.0 software package. A
dissociation constant (Kd) of 7.8310
210 M is obtained for E3BD bind-
ing to E3 as derived from the competitive binding data (see Supple-
mental Experimental Procedures). The absence of heat changes
with LBD-SBDp is consistent with the inability of SBDp to bind E3.structure refined to an Rfree of 0.247 and has good ge-
ometry (Table 1). The E3BD/E3 interface buries approx-
imately 1,490 A˚2 of the E3 and E3BD surfaces. Residues
130–172 of E3BD (Figures 3B and 3C) and nearly all of
the E3 residues are visible in electron-density maps.
The well-ordered residues 121–129 and 173–180 in the
structure of the E3BD construct alone are not visible in
the E3BD/E3 complex and are assumed disordered.
Based on proteolysis results and homology to SBDs,
the human E3BD had previously been surmised to con-
sist of residues 131–163 (Harris et al., 1997). In this study,
residues 130–170 were chosen as the boundaries of
E3BD, because residue 130 makes contact to E3, and
the side chain of residue 170 is the last to interact with
a neighboring secondary structural element of E3BD.
At merely 41 residues, E3BD and the structurally homol-
ogous SBDs represent one of the smallest known fold-
ing units (Perham, 2000).
Because E3 is a homodimer, two putative binding
sites are available for E3BD (Figure 3D). However, only
one E3BD binds to the E3 homodimer in the E3BD/E3
structure (Figures 3A and 3B), which confirms the ITC
data. This stoichiometry results from the fact that por-
tions of E3BD bind across the local 2-fold axis present
in E3, thereby contacting residues in both monomers
of the homodimer nonequivalently (Figure 4A). With an
E3BD bound in this configuration, a second E3BD at-
tempting to access the second binding site on E3 would
be sterically excluded by the first. This method of en-
forcing the stoichiometry of binding is similar to that ob-
served in Geobacillus SBDp bound to its cognate E1p or
E3 (Frank et al., 2004; Mande et al., 1995). The location of
the E3BD binding site on human E3 does not obstruct
the binding sites for the enzyme’s substrates; indeed,
it is possible to soak NADH into the E3BD/E3 crystals
and observe electron density (data not shown) for this
substrate bound at its normal binding site (Brautigam
et al., 2005). The surface area on E3BD buried at the
E3BD/E3 interface is approximately 785 A˚2. About 27%
of the total surface of E3BD (2900 A˚2) is therefore in-
volved in this interaction.
Comparison of the structures of E3 in the E3BD/E3
complex versus human E3 alone (Brautigam et al.,
2005) reveals that E3 is essentially unperturbed when
bound to E3BD; the r.m.s. deviation of the Ca atoms of
the two structures is only 0.3 A˚. Likewise, E3BD main-
tains essentially the same fold in crystal structures alone
and when bound to E3 (Figure 1B); the r.m.s. deviation of
the two sets of Ca atoms is 0.7 A˚. The secondary struc-
ture of E3BD undergoes a small change when bound to
E3. L0 is slightly larger (residues 130–134) and H1 slightly
smaller (residues 135–141) in the bound form of E3BD
compared to E3BD alone. The other local changes in
both E3 and E3BD are the movements of side chains to
accommodate and facilitate binding. In contrast to the
Geobacillus SBDp/E3 structure (Mande et al., 1995),
there is no change in the active site of E3 when E3BD
binds. Both E3 and E3BD appear to be rigid structural
units that associate as a consequence of their surface,
electrostatic, and hydrogen bonding compatibility.
Many of the interactions between human E3 and the
side chains of E3BD are made between residues in the
L0 and L2 regions of E3BD and residues from the inter-
face domain (Brautigam et al., 2005) of E3 (Figures 4A
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615Figure 3. Crystal Structure of the E3BD/E3
Complex
(A) Ribbon representation of the structure.
Shown are the monomers of E3 (blue, tan),
E3BD (green), and FAD (black sticks).
(B) Electron density for E3BD. A close-up of
the structure in the same orientation as in
part (A) is shown. The ball-and-stick model
represents the refined coordinates of E3BD.
Superposed on this is a 2Fo-Fc electron-
density map contoured at the 1-s level.
(C) A closer, stereo view of the map shown in
part (B).
(D) The overlap of the two E3BD binding sites.
A surface representation of E3 is shown in an
orientation rotated 90º around the horizontal
axis with respect to that of part (A). A ribbon
diagram of E3BD (green) is shown, and a sec-
ond theoretical molecule (E3BD*), generated
by rotating the green monomer about the
dyad axis of E3, is shown in yellow. The sur-
face is colored as above, except for the sur-
face in contact with the green E3BD (purple),
that contacting the yellow E3BD (blue), and
that contacting both (orange).and 4B). Both helices H1 and H2 of E3BD are also in-
volved in the interaction. A complex network of interac-
tions between the E3 homodimer and E3BD occurs very
close to the dyad axis of E3. Y438 (one monomer) and
Y4380 (the other monomer) stack on one another, form-
ing a platform onto which residues from E3BD (desig-
nated P133bd, P154bd, and I157bd) stack (Figure 4A).
The side chain of R130bd makes a hydrogen bond to
Y4380 and an ionic contact to D444. The equivalent
D4440 is in a position to hydrogen bond with S132bd
and the main chain oxygen of P133bd. The guanidinium
moiety of R4470 stacks on the side chain of N137bd in-
stead of forming a hydrogen bond with it, as might be
expected. Also, two residues from H2 of E3BD contact
E3; the side chain K160bd forms hydrogen bonds withthe side chains of E4430 and D4130, while the side chains
of E161bd and T4120 stack on one another (Figure
4B). These interactions are noteworthy because in the
Geobacillus SBDp/E3 structure, H2 does not interact
with E3 (Mande et al., 1995).
Binding Studies of E3BDs Mutated
at the E3BD/E3 Interface
Further characterization of the E3BD/E3 interface was
carried out by site-directed mutagenesis of interfacial
residues in the LBD-E3BD construct. The structural in-
tegrity of all of the mutant proteins was ascertained us-
ing CD spectroscopy; all had spectra that were similar
to wild-type LBD-E3BD (data not shown). The binding
of the mutant LBD-E3BD proteins to human E3
Structure
616Figure 4. Interactions between E3 and E3BD
(A) Stereo diagram of selected interactions.
Carbons from E3 are colored tan or light
blue, depending on their monomer of origin.
Secondary structure is shown semitranspar-
ently. The local 2-fold axis of E3 is shown as
a black cylinder.
(B) The interactions of residues in helix H2 of
E3BD (numbers with bd) with those from E3.
(C) Dissociation constants (Kd) for the binding
of wild-type and mutant E3BD to E3 deter-
mined by ITC. DDGA is also shown. NM, not
measurable.
(D) Location of site-directed mutations in
E3BD. A surface representation of E3BD with
residues color-coded according to the magni-
tude of DDGA (in units of kcal/mol) caused by
their mutations to alanine (or methionine, in
the case of A134bd). Red, DDGA > 4.6; yellow,
4.6 > DDGA > 4.0; green, 4.0 > DDGA > 3.0;
blue, 3.0 > DDGA > 2.0. The total surface for
E3 binding is outlined in orange. Locations of
residues are labeled on the surface.was measured using ITC. The binding of E3BDs contain-
ing the mutations S132Abd, P133Abd, A134Mbd,
N137Abd, and I157Abd to E3 could not be measured
by ITC, because heat changes upon their titration into
solutions of E3 were too small (Figure 4C). Presumably,
this loss of enthalpy is due to a severe diminution in the
ability of these mutants to bind E3. All of these residues
contact the E3 homodimer near to its dyad axis, and they
make either van der Waals or uncharged polar interac-
tions with E3 (Figure 4A). The binding of K160Abd to
E3 is measurable; its dissociation constant is raised
four orders of magnitude compared to that of wild-
type E3BD (Figure 4C). This residue is not as close to
the 2-fold axis of E3 as those mentioned above, but it
is the only basic residue of E3BD to interact with two
acidic residues of E3 (Figure 4B). Other residues at theinterface, R130bd, R136bd, E140bd, R155bd, and
E161bd were mutated to alanine, and each mutation di-
minishes the binding affinity by 2–3 orders of magnitude
(Figure 4C), indicating that they are also important to the
interaction. In sum, these mutational data validate the
E3BD/E3 interface observed crystallographically.
It may seem counterintuitive that the mutation of res-
idues involved in modest hydrogen bonding or stacking
interactions apparently causes abolition of E3BD bind-
ing (Figures 4A–4C). Nonetheless, similar behavior has
been detected at other protein-protein interfaces
(Chen and Shapiro, 1997; Clackson and Wells, 1995;
Schreiber and Fersht, 1995). Many protein-protein inter-
faces feature mutational ‘‘hot spots.’’ A hot spot is gen-
erally defined as a residue whose mutation to alanine
causes a large change in the association free energy
Crystal Structures of E3BD and E3BD-E3 Complex
617(DDGA = RT ln (Kd(mutant)/Kd(wild-type))) of two proteins
(Clackson and Wells, 1995). Figure 4D shows that the
residues causing the largest DDGAs upon mutation
(DDGA > 4.6 kcal/mol; i.e., those whose binding charac-
teristics are not measurable) are located in a swath
along the middle of the E3BD/E3 interface. Mutation of
residues on the periphery of the interface has a smaller
effect on DDGA. Thus, the present binding results vali-
date the ‘‘hot-spot’’ paradigm previously proposed for
other protein-protein interfaces: the mutations of resi-
dues in the center of the interface cause the largest
changes in binding energy (Bogan and Thorn, 1998;
Clackson and Wells, 1995). The theoretical underpin-
nings of this phenomenon are not well understood;
they may involve the necessity of excluding solvent
from the center of the interaction (Bogan and Thorn,
1998) or the ease with which water may substitute for
a lost interaction (DeLano, 2002).
Comparisons between E3BD/E3 and Geobacillus
SBDp/E3 Interfaces
A comparison of the human E3BD/E3 complex to the
Geobacillus SBDp/E3 complex reveals that, in both
cases, the H1 helices of the binding domains intimately
contact the respective E3s (Figure 5). Both H1s interact
using polar and apolar contacts. The sequences of the
binding domains and their binding sites on the E3s are
not well conserved (Figure 1D); thus, the identity of the
residues that form the aforementioned interactions
varies between the two species. The positions of the
H2 helices of the binding domains with respect to the re-
spective E3s are divergent. The H2 of the Geobacillus
SBDp/E3 complex is oriented away from the surface of
E3, but in the human E3BD/E3 complex, H2 is closer to
E3 (Figure 5). Indeed, as noted above, residues from
H2 of E3BD contact human E3 (Figure 4B). The orienta-
tion of E3BD with respect to E3 is not influenced by crys-
tal contacts. This fact is evidenced by the observation
that, in the E3BD/E3 asymmetric unit, all nine E3BDs
are nearly identically oriented despite differences in their
crystalline environments.
The binding sites for the binding domains on the re-
spective E3s also differ. In the Geobacillus SBDp/E3
complex, SBDp comes close to the dyad axis of E3,
but does not cross it. Pairs of residues related by this
axis are not contacted by Geobacillus SBDp. However,
parts of E3BD do cross the dyad axis of E3, and they
do contact 2-fold-related pairs of residues nonequiva-
lently (Figures 3C and 4A). In this respect, the E3BD/E3
complex is like the Geobacillus SBDp/E1p complex
(Frank et al., 2005). The extent of contact for the binding
domains on human E3, Geobacillus E3, and Geobacillus
E1p varies. Calculations performed using CNS show
that the total surface area buried by the coupling of
the Geobacillus SBDp and E1p is only 1030 A˚2, com-
pared to 1240 A˚2 for the Geobacillus SBDp/E3 complex
and 1490 A˚2 for the human E3BD/E3 complex.
Figure 1D shows an alignment of human E3BD and
Geobacillus SBDp, with residues that contact the re-
spective E3s (and Geobacillus E1p) marked with differ-
ent symbols. This analysis demonstrates that the posi-
tions, if not the identities, of many of the residues that
contact E3s are conserved in these diverse species;
the positions of 7 out of 12 human E3BD/E3 contactsare recapitulated at the Geobacillus E3/SBDp interface.
As noted before (Frank et al., 2005), many of the same
residues used to contact Geobacillus E3 are used to
associate with Geobacillus E1p (Figure 1D). These inter-
actions explain the mutually exclusive mode in which
Geobacillus E3 and E1p bind to the SBDp. Moreover,
in this sequence alignment, T152bd, G153bd, and
D162bd are invariant, but do not make contact with
a binding partner. Instead, these residues play impor-
tant structural roles within the three binding domains,
explaining their conservation.
Analysis of Disease-Causing Mutations in Human E3
Several mutations in human E3 are known to result in
combined enzyme deficiencies in a-ketoacid dehydro-
genase complexes PDC, BCKDC and KGDC (Hengeveld
and de Kok, 2002). Among the E3 missense mutations
reported to date, E340K (Hong et al., 1997), D444V
(Shany et al., 1999), R447G (Odievre et al., 2005), and
R460G (Hong et al., 1996) are close to the E3BD binding
site (Figure 6A). All four residues make intermonomer
contacts in the human E3 homodimer. It has been spec-
ulated that these mutations diminish E3 activity by dis-
rupting the ability of the enzyme to form homodimers
(Brautigam et al., 2005; Hengeveld and de Kok, 2002)
or by interfering with E3-E3BP interactions (Odievre
et al., 2005).
We examined the effects of these mutations on E3BD
binding to E3. Analyses of the proteins carrying the
E340K, D444V, R447G, and R460G mutations using an-
alytical ultracentrifugation show that they have no effect
on the dimerization of human E3. The wild-type and mu-
tant E3s have similar dissociation constants (Kd = 2–33
1027 M) at 20ºC for the monomer-dimer equilibrium (data
not shown). Except for R460G, the recombinant mutant
proteins expressed at 28ºC exhibit essentially wild-type
E3 activity (Figure 6B). These results differ from those
measured with cultured cells from E3-deficient patients
carrying these mutations, which showed markedly re-
duced E3 activity (Hong et al., 1997; Odievre et al.,
2005; Shany et al., 1999). A plausible explanation of this
discrepancy is that these missense mutations render
these E3 variants unstable in patients’ cells at 37ºC. PDC
activity reconstituted with E340K, D444V, and R447G E3
Figure 5. Comparison of the Geobacillus SBDp/E3 and E3BD/E3
Structures
The Ca atoms of Geobacillus E3 and human E3 (not the binding
domains) were used for this superposition. The coloration is that
of Figure 3, and the Geobacillus SBDp is orange.
Structure
618variants is reduced to 38%, 12%, and 28% of the wild
type, respectively (Figure 6B). Moreover, the activity
of human BCKDC is impaired when reconstituted with
human E3 variants carrying the D444V and E340K muta-
tions (data not shown). The results suggest that these E3
variants interact with binding domains poorly, thereby
impeding the recruitment of E3 to the PDC or the
BCKDC. This notion is confirmed by ITC measurements,
which show that the affinities of the mutant E3 proteins
for E3BD are severely reduced (Figure 6C). The Kd for
R447G is two orders of magnitude higher than that of
the wild-type protein. The heat changes for the interac-
tions between E3BD and E340K and D444V are too weak
to be detected. It is therefore likely that poor recruitment
of E3 into PDC accounts at least partially for the poor
PDC activity detected in human patients carrying these
mutations. For the R460G mutant E3, the Kd is three or-
ders of magnitude higher than that of wild-type E3. The
Figure 6. Human Mutations Causing E3 Deficiency
(A) The surface of the human E3 homodimer is shown as in Figure 3.
One of the E3BD binding sites is outlined in orange. Disease-causing
mutations are colored dark blue (E340), red (D444), yellow (447), and
magenta (R460).
(B) Enzyme activities of wild-type and mutant human E3s. The black
bars represent E3 activity, the speckled bars show PDC activity re-
constituted with wild-type and mutant E3. The identities of the E3s
used are shown on the x axis. Activities are normalized to that of
the wild-type enzymes, which at 100% are 314 s-1 for human E3
and 401 min-1 for the overall activity of the reconstituted PDC.
(C) Dissociation constants (Kd) for the binding of wild-type and mu-
tant E3 to LBD-E3BD as determined by ITC. NM, not measurable.weak binding of this mutant E3 to E3BD is compounded
by its low dihydrolipoamide dehydrogenase activity,
yielding no detectable PDC activity. The side chain of
R460 contacts the side chain of E3330, and both residues
are mostly buried in the human E3 structure (Figure 6A).
Removal of the bulky, charge-compensating argininyl
side chain, as in the R460G mutant, may therefore cause
a significant structural rearrangement that diminishes
both E3 activity and E3BD binding.
Concluding Remarks
The conserved folds of E3BD, Geobacillus SBDp and
E. coli SBDk (Figure 1C) suggest that the E3BP arose
from its cognate E2p through gene duplication; in sup-
port of this is the fact that the genes for both human
E3BP and E2p are located on chromosome 11 (Harris
et al., 1997). The structural role of E3BP in tethering E3
to the icosahedral 60-meric E2p/E3BP core of the eu-
karyotic PDC (Harmych et al., 2002; Maeng et al., 1996;
Seyda and Robinson, 2000) is confirmed by the binding
studies presented herein (Figure 2). Three different strat-
egies are employed by a-ketoacid dehydrogenase com-
plexes to sequester the essential E1 and E3 components
to the E2 core. Eukaryotic PDC uses E3BP to secure E3,
and the SBDp of E2p binds E1p (Reed, 2001). In the
mammalian KGDC, there is biochemical evidence that
the E3 binds to the amino-terminal region of the cognate
E1k homodimer, allowing the separation of a stable
E1k-E3 subcomplex from the octahedral E2k core
(McCartney et al., 1998; Rice et al., 1992; Sanderson
et al., 1996). In the Geobacillus PDC, both E1p and E3
sterically compete for essentially the same binding site
on the SBDp domain of the 60-meric E2p scaffold
(Figure 1D). Similarly, the single SBD in the octahedral
24-meric E2b core of the mammalian BCKDC, which is
devoid of E3BP, also binds both of its respective E1b
and E3 components, albeit with markedly lower affinity
for E3 than E1b (Pettit et al., 1978). Thus, while the over-
all molecular architecture and mechanism of a-ketoacid
dehydrogenase complexes is conserved, the mode of
binding for the common E3 component has diverged
to accommodate the special organizational and func-
tional requirements of each catalytic machine.
Experimental Procedures
Protein Expression, Purification, and Site-Directed Mutagenesis
Recombinant human E3 was expressed and purified as previously
described (Brautigam et al., 2005). To facilitate expression, a re-
combinant fusion protein LBD-E3BD was produced. This construct
comprises the LBD from the E2b of human BCKDC, followed by res-
idues 121–175 of human E3BP, which harbors the entire E3BD
sequence (residues 130–170), and eight vector-derived residues in-
cluding the 6 x His-tag at its C terminus. A tobacco-etch virus (TEV)
protease recognition sequence (LENLYFQ YG) was introduced into
the connecting region immediately 50 to residue 121. The SBDp pro-
tein (E2p residues 260–315) of human PDC was also expressed as
a C-terminal fusion protein to LBD of human BCKDC (LBD-SBDp),
containing a TEV-cleavage site similar to LBD-E3BD. LBD-E3BD
and LBD-SBDp proteins were isolated from E. coli lysates by Ni-NTA
(Qiagen) extraction and Sephadex S-200 gel filtration.
The LBD-E3BD fusion protein was digested with TEV protease fol-
lowed by re-extraction with Ni-NTA resin. The resultant E3BD pro-
tein was further purified on a Sephacryl S-100 size-exclusion column
that had been equilibrated with a buffer containing 50 mM potassium
phosphate (pH 7.5), 150 mM KCl, and 5% (v/v) glycerol.
Crystal Structures of E3BD and E3BD-E3 Complex
619To prepare the E3BD/E3 complex for crystallization, purified hu-
man E3 and E3BD proteins were mixed at the ratio of one E3 dimer
to two E3BD monomers. The mixture was transferred to a buffer
consisting of 20 mM HEPES (pH 7.5) and 20 mM b-mercaptoethanol,
and concentrated to 25 mg/ml.
Mutations in E3 and LBD-E3BD were introduced using the Quick-
Change kit (Stratagene), according to the manufacturer’s protocols.
Crystallization and Structure Determination
Crystals of E3BD were obtained using the vapor diffusion method at
20ºC by mixing 2 ml E3BD (33 mg/ml) with 2 ml well solution contain-
ing 1.35M sodium citrate (pH 6.3) and 0.05%–0.075% (w/v) b-octyl-
glucopyranoside. Microseeding was used to induce crystal growth.
Cryostabilization was accomplished by transferring the crystals to
well solution containing 10% (v/v) glycerol. The 300–500 mm pyra-
midal crystals have the symmetry of space group P6522. Crystals
were flash-cooled by plunging them into liquid propane.
Hanging drops of the E3BD/E3 complex consisted of 3 ml of the
protein solution and 3 ml of the well solution containing 14% (w/v)
polyethylene glycol 4000, 0.2M (NH4)2SO4, 0.1M sodium acetate
(pH 4.6), 0.03M spermidine and 6%–8% glycerol. Crystallization
was induced by streak seeding after the drops were equilibrated
for 24 hr at 20ºC. The rod-like crystals have typical dimensions of ap-
proximately 500 3 50 3 50 mm and have the symmetry of space
group P212121. Cryo-cooling of the crystals was carried out at 4ºC
with 20% (v/v) glycerol added to the well solution to serve as the
cryoprotectant. After this step, the crystals were flash-cooled in
liquid propane.
X-ray diffraction data from crystals of E3BD and the E3BD/E3
complex were collected at beamline 19-ID at the Structural Biology
Center (SBC) of the Advanced Photon Source (APS) at Argonne Na-
tional Laboratory (ANL). The data were integrated and scaled using
the HKL2000 package of programs (Otwinowski and Minor, 1997).
The E3BD/E3 complex structure was determined using the molecu-
lar-replacement protocols available in CNS version 1.1, as outlined
above (Brunger et al., 1998). Refinement of the E3BD/E3 model pro-
ceeded using the simulated annealing, conjugate-gradient minimi-
zation, and individual B-factor refinement protocols available in
CNS. The model was manipulated using the program XtalView
(McRee, 1992). The final model contains ten nearly complete chains
of human E3 and nine chains of E3BD (eight of which have occu-
pancy < 1). The positions of the E3BD molecules have been verified
using simulated-annealing omit maps.
The structure of E3BD alone was determined using molecular re-
placement. The search model utilized was that of E3BD associated
with the AB dimer, as discussed above. Phaser (Read, 2001; Storoni
et al., 2004) was used to locate a single monomer of E3BD in the
asymmetric unit of these crystals. The search model represented
only 75% of the residues present in the E3BD protein construct;
electron density was evident for additional residues after rigid-
body refinement in CNS of the molecular replacement model. These
residues were added to the model, which was subjected to refine-
ment in CNS as outlined above. Alternate conformations of several
residues were included in the refinement. The final model of E3BD
alone contains 60 amino-acid residues. In addition, elongated elec-
tron density is present along a crystallographic 2-fold axis in Fo - Fc
maps, with a maximum extent of 6 s. Attempts to model buffer con-
stituents into this density raised Rfree; it therefore remains unmod-
eled. Final statistics of the model are in Table 1.
Supplemental Data
Supplemental Data including additional Experimental Procedures
are available at http://www.structure.org/cgi/content/full/14/3/611/
DC1/.
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Note Added in Proof
Shortly before the publication of this work, a study reporting the
2.6 A˚ structure of E3 in complex with a different construct of E3BP
from human PDC appeared [Ciszak, E.M., Makal, A., Hong, Y.S., Vet-
taikkorumakankauv, A.K., Korotchkina, L.G., and Patel, M.S. (2006).
How Dihydrolipoamide dehydrogenase-binding protein binds dihy-
drolipoamide dehydrogenase in the human pyruvate dehydroge-
nase complex. J. Biol. Chem. 281, 648-655].
